Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses.
In specialty pharmaceuticals, it is the third largest radiopharmaceutical manufacturer with second largest commercial radio pharmacy network in US. It is the second biggest player in the allergenic extract market in the US
In CDMO (CMO, APIs) Jubilant is engaged in CMO of sterile injectables, ophthalmics, otics and ointments, creams and liquids
Revenue break up (FY22)- Generics - 19%, Specialty Pharma –43%, CDMO Sterile Injectable – 21% and CRDMO (CDMO-API + Drug Discovery) – 17%
Q1FY23
Traction in specialty pharmaceuticals and CRDMO was offset by muted numbers in CDMO sterile injectables and generics
Revenues were down 11% YoY to ₹ 1452 crore
EBITDA was at ₹ 192 crore, down 49% YoY with margins at 13.3%
Pharmaceuticals company Jubilant Pharmova announced Q3FY24 & 9MFY24 results:
Revenue and Income:
- Total income for Q3FY24 increased by 10% YoY to Rs 1,713 crore.
- EBITDA for Q3FY24 grew by 63% YoY to Rs 254 crore with EBITDA margin expansion of 490 basis points YoY.
- The company reported a Profit After Tax (PAT) of Rs 66 crore in Q3FY24, showing a remarkable improvement compared to a PAT of (Rs 16 crore) in Q3FY23.
- For 9MFY24, total income rose 8% YoY to Rs 4,999 crore.
- EBITDA for 9MFY24 showed a 16% increase YoY, reaching Rs 684 crore with a 100 basis point margin expansion.
Segment Performance:
- Radiopharma revenue in Q3FY24 grew by 23% to Rs 752 crore and EBITDA increased significantly by 153% to Rs 161 crore.
- Allergy Immunotherapy revenue for Q3FY24 saw a 9% increase to Rs 161 crore, with EBITDA rising by 16% to Rs 62 crore.
- CDMO Sterile Injectables Q3FY24 revenue increased by 11% to Rs 303 crore, though EBITDA for Q3FY24 was affected by planned extended shutdowns, expected to improve in Q4.
- CRDMO Q3FY24 revenue stood at Rs 252 crore, with EBITDA margins at 16% despite facing industry headwinds.
- Generics segment Q3FY24 revenue was reported at Rs 199 crore with an improving EBITDA trend.
Debt:
- Total Gross Debt as of December 31, 2023, was reported at Rs 3,419 crore. showing a slight increase compared to Rs 3,410 crore. as of March 31, 2023.
Key Priorities and Future Outlook:
- Focus on leveraging the Radiopharma segment's stable and high-margin core portfolio for continuing leadership in North America.
- Spotlight on Allergy Immunotherapy market share growth in the US through venom immunotherapy and expanding in non-US markets.
- In CDMO Sterile Injectables, emphasis on executing a $370 million capacity expansion to support projected market growth.
- In Generics, steps toward enhancing quality and engagement with the US FDA for Import Alert resolution at the Roorkee facility.
- In CRDMO, the objective is to drive new customer acquisitions and invest in capabilities to improve productivity.
- For Proprietary Novel Drugs, focus on progressing clinical trials for LSD1/HDAC6 inhibitors and capitalizing on strategic opportunities for non-dilutive funding.
Sustainability Initiatives:
- The company has entered into a power purchase agreement to meet 90% of its electricity demand from renewable sources for its facilities in Karnataka.
Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA.
The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients.
Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures.
The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.
Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA.
The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients.
Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures.
The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.
Jubilant Pharmova share price as on 20 Apr 2024 is Rs. 665. Over the past 6 months, the Jubilant Pharmova share price has increased by 62.39% and in the last one year, it has increased by 110.18%. The 52-week low for Jubilant Pharmova share price was Rs. 299.05 and 52-week high was Rs. 724.4.
You can buy Jubilant Pharmova Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jubilant Pharmova Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Apr 19, 2024 03:54 PM the closing price of Jubilant Pharmova Ltd was ₹ 665.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 19, 2024 03:54 PM, the market cap of Jubilant Pharmova Ltd stood at ₹ 10,592.19.
Invest
FAQ’s on Jubilant Pharmova Ltd Shares
